Coronary Microvascular Dysfunction, Coronary Artery Vasospasm
Conditions
Brief summary
The goal of this prospective, multicenter registy is to describe the 'real-world' use of coronary function tests, which may consist of bolus thermodilution measurements of coronary microvascular function and/or invasive vasoreactivity tests with acetylcholine, in the current Belgian routine practice. The main questions it aims to answer are: * how frequent are coronary function tests performed * what is the indication for coronary function tests * what is the frequency of coronary microvascular dysfunction * what is the frequency of coronary artery vasospasm From each participant, data will be collected from their medical files concerning cardiovascular risk factors, relevant past medical history, non-invasive tests, procedural data, and follow-up data from routine in-patient visits. Their are no specific study visits. Optionally, patients will be asked to fill in questionnaires about anginal symptoms and quality of life.
Interventions
DIAGNOSTIC_TESTCoronary Function Test
Coronary function test may comprise of bolus thermodilution measurements of coronary microvascular function and/or acetylcholine-derived coronary vasoreactivity tests.
Sponsors
University Hospital, Antwerp
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient scheduled for coronary function test, comprising of intracoronary bolus thermodilution measurements of microvascular function, and/or intracoronary vasoreactivity tests with acetylcholine. * Subject understands the study requirements and provides written informed consent.
Exclusion criteria
* Subject is participating in another investigational clinical trial that may cause non-compliance with the protocol or confound data interpretation. * Subject intends to participate in another investigational clinical trial that may cause non-compliance with the protocol or confound data interpretation. * Documented or suspected pregnancy. * Inability to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of coronary microvascular dysfunction and/or coronary artery vasospasm | 5 years | To measure the frequency of coronary microvascular dysfunciton coronary artery and vasomotor disorders among patients undergoing coronary function tests. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Describe predictors for coronary microvascular dysfunction and/or coronary artery vasospasm | 5 years | To find predictors for coronary microvascular dysfunction and/or coronary artery vasospasm by means of multivariate regression analysis. |
| Describe 1- year and 3-year MACE among the different endotypes of coronary microvascular dysfunction with/whithout coronary artery spasm. | 5 years | To describe the difference in 1-year and 3-year MACE between the different endotypes of coronary microvascular dysfunction obtained. |
Countries
Belgium
Outcome results
None listed